SCHEMBL3038360

SCHEMBL3038360

CSc1nc(Cl)cc(NN)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
GAA P10253 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
POLB P06746 1/20 0.42
HTT P42858 1/20 0.40
AURKA O14965 2/20 0.38
AURKB Q96GD4 2/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPT P10636 1/20 0.35
PPARA Q07869 6/20 0.34
PPARG P37231 5/20 0.33
RXRA P19793 4/20 0.33
RXRG P48443 4/20 0.33
RXRB P28702 3/20 0.33
PPARD Q03181 3/20 0.33
HSP90AA1 P07900 2/20 0.33
KDM4E B2RXH2 1/20 0.32
ABCC4 O15439 1/20 0.32
ABCB11 O95342 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31073527 1.00 KMT2A (0.56) KMT2AMEN1GAASMN1; SMN2POLB
SCHEMBL31073526 1.00 KMT2A (0.56) KMT2AMEN1GAASMN1; SMN2POLB
SCHEMBL2614898 0.82 KMT2A (0.57) KMT2AMEN1GAASMN1; SMN2POLB
SCHEMBL13638236 0.81 KMT2A (0.55) KMT2AMEN1GAASMN1; SMN2POLB
SCHEMBL19686555 0.79 KMT2A (0.54) KMT2AMEN1GAASMN1; SMN2POLB
SCHEMBL62021 0.79 POLB (0.53) KMT2AMEN1GAASMN1; SMN2POLB
SCHEMBL9538339 0.78 KMT2A (0.62) KMT2AMEN1GAAPOLBHTT
SCHEMBL11001844 0.78 MEN1 (0.41) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL12781970 0.78 MEN1 (0.41) KMT2AMEN1GAASMN1; SMN2HTT
SCHEMBL11371064 0.78 KMT2A (0.53) KMT2AMEN1GAASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264161-B2 Heterocyclic adenosine receptor antagonists EXELIXIS, INC. (US) 2025-04-01 US disclosed
US-20230382917-A1 Heterocyclic Adenosine Receptor Antagonists EXELIXIS, INC. 2023-11-30 US disclosed
US-20230382917-A1 Heterocyclic Adenosine Receptor Antagonists EXELIXIS, INC. 2023-11-30 US disclosed
US-20230382917-A1 Heterocyclic Adenosine Receptor Antagonists EXELIXIS, INC. 2023-11-30 US disclosed
US-11718622-B2 Heterocyclic adenosine receptor antagonists EXELIXIS INC. (US) 2023-08-08 US disclosed
US-11718622-B2 Heterocyclic adenosine receptor antagonists EXELIXIS INC. (US) 2023-08-08 US disclosed
US-11718622-B2 Heterocyclic adenosine receptor antagonists EXELIXIS INC. (US) 2023-08-08 US disclosed
EP-3611174-B1 [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR MEDSHINE DISCOVERY INC (CN) 2022-06-08 EP disclosed
US-20210292332-A1 Heterocyclic Adenosine Receptor Antagonists EXELIXIS, INC. 2021-09-23 US disclosed
US-20210292332-A1 Heterocyclic Adenosine Receptor Antagonists EXELIXIS, INC. 2021-09-23 US disclosed
EP-0121341-B1 TRIAZOLO(4,3-C)PYRIMIDINES AND TRIAZOLO(1,5-C)PYRIMIDINES SUBSTITUTED BY NITROGEN-CONTAINING HETEROCYCLIC RINGS RIKER LABORATORIES, INCORPORATED (US) 1988-11-17 EP disclosed
US-4612375-A Substituted 4-hydrazino-pyrimides as intermediates for triazolo [4,3-c]pyrimidines RIKER LABORATORIES, INC. (US) 1986-09-16 US disclosed
US-4572910-A BRONCHODILATORS RIKER LABORATORIES, INC. (US) 1986-02-25 US disclosed
US-4536579-A BRONCHODILATING AGENTS RIKER LABORATORIES, INC. (US) 1985-08-20 US disclosed
US-4532242-A Bronchodilator agents RIKER LABORATORIES, INC. (US) 1985-07-30 US disclosed
US-4528288-A Substituted triazolo[1,5-c]pyrimidines RIKER LABORATORIES, INC. (US) 1985-07-09 US disclosed
US-4477450-A BRONCHODILATORS RIKER LABORATORIES, INC. (US) 1984-10-16 US disclosed
EP-0121341-A1 Triazolo(4,3-c)pyrimidines and triazolo(1,5-c)pyrimidines substituted by nitrogen-containing heterocyclic rings RIKER LABORATORIES, INCORPORATED (US) 1984-10-10 EP disclosed
EP-0021939-B1 HYDRAZINO (OR AZIDO) 5-ALKYLTHIO PYRIMIDINES, PROCESSES FOR THEIR PREPARATION AND THEIR USES AS HERBICIDES AND FONGICIDES P C U K PRODUITS CHIMIQUES UGINE KUHLMANN (FR) 1983-01-12 EP disclosed
EP-0021939-A1 Hydrazino (or azido) 5-alkylthio pyrimidines, processes for their preparation and their uses as herbicides and fongicides P C U K PRODUITS CHIMIQUES UGINE KUHLMANN (FR) 1981-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292332-A1 Heterocyclic Adenosine Receptor Antagonists ADORA2A, ADORA1, ADORA3 KMT2A 3650/4885MEN1 4346/4885GAA 1187/4885
US-20230382917-A1 Heterocyclic Adenosine Receptor Antagonists ADORA2A, ADORA1, ADORA3 KMT2A 3650/4885MEN1 4346/4885GAA 1187/4885
US-11718622-B2 Heterocyclic adenosine receptor antagonists ADORA2A, ADORA1, ADORA3 KMT2A 3650/4885MEN1 4346/4885GAA 1187/4885
US-12264161-B2 Heterocyclic adenosine receptor antagonists ADORA2A, ADORA1, ADORA3 KMT2A 3650/4885MEN1 4346/4885GAA 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.